CovidChloroV1, Main, Corpus, bibRecord, 001104

The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series.

Identifieur interne : 001104 ( Main/Corpus ); précédent : 001103; suivant : 001105

The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series.

Auteurs : Satish Tadepalli ; Jagan Mohan Rao Vanjarapu ; Anna De Dona ; Pramil Cheriyath ; Vinod Nookala

Source :

Cureus [ 2168-8184 ] ; 2020.

RBID : pubmed:32685300

Abstract

An outbreak of severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection started in December 2019 in China that resulted in a global health emergency. The World Health Organization later named the disease as coronavirus disease 2019 (COVID-19). Currently, there is no effective treatment available and the data are evolving through continuous clinical trials and ongoing research. Severe infections present with hypoxemic respiratory failure from acute respiratory distress syndrome as one of the major complications. We report two cases of COVID-19 patients who initially presented with moderate to severe symptoms. Later, their clinical course worsened despite ongoing treatment with multiple medications such as hydroxychloroquine and azithromycin until they were started on tocilizumab. Within a short period after they were administered tocilizumab, their oxygen saturation improved and other inflammatory markers such as D-dimer levels, lactate dehydrogenase, and ferritin levels decreased. There is an increase in the amount of research citing the role of various cytokines in the pathophysiology of COVID-19. Targeting the inflammatory mediators in the pathogenesis, especially interleukin-6 pathway inhibitors, would improve overall morbidity and mortality, thus decreasing the burden on healthcare systems.

DOI: 10.7759/cureus.8631
PubMed: 32685300
PubMed Central: PMC7364429

Links to Exploration step

pubmed:32685300

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series.</title>
<author><name sortKey="Tadepalli, Satish" sort="Tadepalli, Satish" uniqKey="Tadepalli S" first="Satish" last="Tadepalli">Satish Tadepalli</name>
<affiliation><nlm:affiliation>Internal Medicine, Hackensack Meridian Health - Ocean Medical Center, Brick, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vanjarapu, Jagan Mohan Rao" sort="Vanjarapu, Jagan Mohan Rao" uniqKey="Vanjarapu J" first="Jagan Mohan Rao" last="Vanjarapu">Jagan Mohan Rao Vanjarapu</name>
<affiliation><nlm:affiliation>Internal Medicine, Hackensack Meridian Health - Ocean Medical Center, Brick, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Dona, Anna" sort="De Dona, Anna" uniqKey="De Dona A" first="Anna" last="De Dona">Anna De Dona</name>
<affiliation><nlm:affiliation>Internal Medicine, Hackensack Meridian Health - Ocean Medical Center, Brick, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cheriyath, Pramil" sort="Cheriyath, Pramil" uniqKey="Cheriyath P" first="Pramil" last="Cheriyath">Pramil Cheriyath</name>
<affiliation><nlm:affiliation>Internal Medicine, Hackensack Meridian Health - Ocean Medical Center, Brick, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nookala, Vinod" sort="Nookala, Vinod" uniqKey="Nookala V" first="Vinod" last="Nookala">Vinod Nookala</name>
<affiliation><nlm:affiliation>Internal Medicine, Community Medical Center, Toms River, USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32685300</idno>
<idno type="pmid">32685300</idno>
<idno type="doi">10.7759/cureus.8631</idno>
<idno type="pmc">PMC7364429</idno>
<idno type="wicri:Area/Main/Corpus">001104</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001104</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series.</title>
<author><name sortKey="Tadepalli, Satish" sort="Tadepalli, Satish" uniqKey="Tadepalli S" first="Satish" last="Tadepalli">Satish Tadepalli</name>
<affiliation><nlm:affiliation>Internal Medicine, Hackensack Meridian Health - Ocean Medical Center, Brick, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vanjarapu, Jagan Mohan Rao" sort="Vanjarapu, Jagan Mohan Rao" uniqKey="Vanjarapu J" first="Jagan Mohan Rao" last="Vanjarapu">Jagan Mohan Rao Vanjarapu</name>
<affiliation><nlm:affiliation>Internal Medicine, Hackensack Meridian Health - Ocean Medical Center, Brick, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Dona, Anna" sort="De Dona, Anna" uniqKey="De Dona A" first="Anna" last="De Dona">Anna De Dona</name>
<affiliation><nlm:affiliation>Internal Medicine, Hackensack Meridian Health - Ocean Medical Center, Brick, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cheriyath, Pramil" sort="Cheriyath, Pramil" uniqKey="Cheriyath P" first="Pramil" last="Cheriyath">Pramil Cheriyath</name>
<affiliation><nlm:affiliation>Internal Medicine, Hackensack Meridian Health - Ocean Medical Center, Brick, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nookala, Vinod" sort="Nookala, Vinod" uniqKey="Nookala V" first="Vinod" last="Nookala">Vinod Nookala</name>
<affiliation><nlm:affiliation>Internal Medicine, Community Medical Center, Toms River, USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Cureus</title>
<idno type="ISSN">2168-8184</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">An outbreak of severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection started in December 2019 in China that resulted in a global health emergency. The World Health Organization later named the disease as coronavirus disease 2019 (COVID-19). Currently, there is no effective treatment available and the data are evolving through continuous clinical trials and ongoing research. Severe infections present with hypoxemic respiratory failure from acute respiratory distress syndrome as one of the major complications. We report two cases of COVID-19 patients who initially presented with moderate to severe symptoms. Later, their clinical course worsened despite ongoing treatment with multiple medications such as hydroxychloroquine and azithromycin until they were started on tocilizumab. Within a short period after they were administered tocilizumab, their oxygen saturation improved and other inflammatory markers such as D-dimer levels, lactate dehydrogenase, and ferritin levels decreased. There is an increase in the amount of research citing the role of various cytokines in the pathophysiology of COVID-19. Targeting the inflammatory mediators in the pathogenesis, especially interleukin-6 pathway inhibitors, would improve overall morbidity and mortality, thus decreasing the burden on healthcare systems.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32685300</PMID>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2168-8184</ISSN>
<JournalIssue CitedMedium="Print"><Volume>12</Volume>
<Issue>6</Issue>
<PubDate><Year>2020</Year>
<Month>Jun</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Cureus</Title>
<ISOAbbreviation>Cureus</ISOAbbreviation>
</Journal>
<ArticleTitle>The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series.</ArticleTitle>
<Pagination><MedlinePgn>e8631</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.8631</ELocationID>
<Abstract><AbstractText>An outbreak of severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection started in December 2019 in China that resulted in a global health emergency. The World Health Organization later named the disease as coronavirus disease 2019 (COVID-19). Currently, there is no effective treatment available and the data are evolving through continuous clinical trials and ongoing research. Severe infections present with hypoxemic respiratory failure from acute respiratory distress syndrome as one of the major complications. We report two cases of COVID-19 patients who initially presented with moderate to severe symptoms. Later, their clinical course worsened despite ongoing treatment with multiple medications such as hydroxychloroquine and azithromycin until they were started on tocilizumab. Within a short period after they were administered tocilizumab, their oxygen saturation improved and other inflammatory markers such as D-dimer levels, lactate dehydrogenase, and ferritin levels decreased. There is an increase in the amount of research citing the role of various cytokines in the pathophysiology of COVID-19. Targeting the inflammatory mediators in the pathogenesis, especially interleukin-6 pathway inhibitors, would improve overall morbidity and mortality, thus decreasing the burden on healthcare systems.</AbstractText>
<CopyrightInformation>Copyright © 2020, Tadepalli et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tadepalli</LastName>
<ForeName>Satish</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Internal Medicine, Hackensack Meridian Health - Ocean Medical Center, Brick, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vanjarapu</LastName>
<ForeName>Jagan Mohan Rao</ForeName>
<Initials>JMR</Initials>
<AffiliationInfo><Affiliation>Internal Medicine, Hackensack Meridian Health - Ocean Medical Center, Brick, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>De Dona</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Internal Medicine, Hackensack Meridian Health - Ocean Medical Center, Brick, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cheriyath</LastName>
<ForeName>Pramil</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Internal Medicine, Hackensack Meridian Health - Ocean Medical Center, Brick, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nookala</LastName>
<ForeName>Vinod</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Internal Medicine, Community Medical Center, Toms River, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Cureus</MedlineTA>
<NlmUniqueID>101596737</NlmUniqueID>
<ISSNLinking>2168-8184</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">covid 19</Keyword>
<Keyword MajorTopicYN="N">hypoxemic respiratory failure</Keyword>
<Keyword MajorTopicYN="N">inflammation</Keyword>
<Keyword MajorTopicYN="N">interleukin (il)-6</Keyword>
<Keyword MajorTopicYN="N">novel coronavirus</Keyword>
<Keyword MajorTopicYN="N">pathophysiology</Keyword>
<Keyword MajorTopicYN="N">pneumonia</Keyword>
<Keyword MajorTopicYN="N">sars-cov-2</Keyword>
<Keyword MajorTopicYN="N">tocilizumab</Keyword>
</KeywordList>
<CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32685300</ArticleId>
<ArticleId IdType="doi">10.7759/cureus.8631</ArticleId>
<ArticleId IdType="pmc">PMC7364429</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jul;92(7):814-818</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32253759</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2015 Jun;74(6):1110-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24834925</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MAbs. 2009 Sep-Oct;1(5):432-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20065633</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ther Adv Musculoskelet Dis. 2010 Oct;2(5):247-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22870451</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):420-422</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32085846</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Mar 12;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32161940</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2010 May;11(5):373-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20404851</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ther Adv Musculoskelet Dis. 2012 Dec;4(6):387-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23227116</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 27;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Feb 24;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Biosci. 2020 Mar 16;10:40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32190290</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001104 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001104 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32685300
   |texte=   The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32685300" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series.

The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki